Group 1 - The company’s wholly-owned subsidiary, Run Du Pharmaceutical (Jingmen) Co., Ltd., has received the veterinary product approval number for "Florfenicol" from the Ministry of Agriculture and Rural Affairs [1][2] - The product is a commonly used veterinary antibiotic with a broad antibacterial spectrum, suitable for large-scale farming operations, primarily used for the prevention and treatment of bacterial diseases in cattle, poultry, pigs, and fish [1][2] - The approval number is valid from April 25, 2025, to April 24, 2030, indicating a significant timeline for market entry [1] Group 2 - The company has obtained the "Veterinary Production License" and "Veterinary GMP Certificate" for the product, indicating readiness for market sales [2] - The approval of Florfenicol will enrich the company’s product line and structure, enhancing its strategic layout in the veterinary medicine sector and improving market competitiveness [3]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has received approval for Fenbendazole oral suspension veterinary drug, enhancing its product line and market competitiveness in the veterinary sector [1][3]. Group 1: Approval Information - The product name is Fenbendazole oral suspension with an approval number of Veterinary Drug No. 110807959, valid from April 25, 2025, to April 24, 2030 [1]. - The product is developed in collaboration with 12 companies and is the first approved new veterinary drug of its kind [1]. - Fenbendazole is a benzimidazole anthelmintic used to treat infections in pigs caused by roundworms, esophageal worms, and whipworms [1]. Group 2: Product Development Timeline - The application for the veterinary drug approval was submitted by Haizheng Animal Health Co., Ltd. on January 11, 2025 [1]. Group 3: Market Position and Strategy - The approval of Fenbendazole oral suspension will enrich the company's veterinary drug product line and structure, aiding in the strategic layout of the veterinary drug sector [3].